Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility Study of Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin in AML Patients With Minimal Residual Disease (MRD)

NCT05000801 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.

NCT NCT05000801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05000801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility Study of Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin in AML Patients With Minimal Residual Disease (MRD)
Lead sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2021
Completion date
July 1, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia